Drug Profile


Alternative Names: Hydrochlorothiazide/aliskiren; Rasilez HCT; Riprazo HCT®; Sprimeo HCT®; Tekturna HCT

Latest Information Update: 16 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Class Antihypertensives; Benzothiadiazines; Fumarates; Small molecules
  • Mechanism of Action Diuretics; Renin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypertension

Most Recent Events

  • 16 Mar 2017 PDL Biopharma has patent protection for Aliskiren/hydrochlorothiazide in USA (PDL Biopharma Annual Reporl,
  • 06 Jul 2016 Noden Pharma completes acquisition of aliskiren/hydrochlorothiazide from Novartis
  • 24 May 2016 Noden Pharma acquires aliskiren/hydrochlorothiazide from Novartis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top